12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALS-2200: Additional Phase I data

Data from a cohort of 8 treatment-naïve patients with chronic HCV genotype 1 infection in a double-blind, placebo-controlled, international Phase I trial showed that once-daily 200 mg ALS-2200 plus ribavirin reduced median HCV RNA levels by 4.18 log10 IU/mL from baseline to day 7. Additionally, 5 patients in the cohort achieved HCV RNA levels below the limit of quantification (<=25 IU/mL) and 2 of the 5 achieved HCV RNA levels below the limit of detection....

Read the full 355 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >